Introduction
T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoproliferative disease with distinctive clinical, morphologic, immunophenotypic and cytogenetic characteristics. [1] [2] [3] Most T-PLLs exhibit a mature post-thymic CD2 þ , CD3 þ , CD7 þ , CD4 þ , CD8À immunophenotypes, but CD4 þ , CD8 þ and CD4À, CD8 þ cases are also commonly seen. 1, 2 The disease follows an aggressive clinical course in most patients with median survival times ranging from 7 to 30 months. 1, 2 The leukemic cells are generally resistant to alkylating drugs, and the most promising treatment results are currently achieved using chemoimmunotherapy protocols combining the anti-CD52 monoclonal antibody alemtuzumab with fludarabine, anthracyclines and alkylating agents. 1, 2, 4, 5 The genetic hallmark of T-PLL is the inversion inv(14)(q11q32) or its variant, the translocation t(14;14)(q11;q32), which are present in up to 80% of the cases. 1, 3, 6 These rearrangements juxtapose enhancer elements of the TCRAD locus in 14q11 next to oncogenes located within the TCL1 locus in 14q32, whose expression is then deregulated. [7] [8] [9] Besides the inv (14) , which is regarded as the primary oncogenic event in T-PLL, [7] [8] [9] [10] the tumor cells usually harbor a high load of additional chromosomal aberrations. 3, 6 These secondary chromosomal aberrations include overrepresentations of 8q and deletions of 8p, frequently due to formation of an isochromosome iso(8q), 3, 6 as well as losses on chromosome 11, 11, 12 and with lower frequency involving other chromosomal regions like 22q and 6q. 3 Although this pattern of secondary changes in inv (14) /t(14;14)-positive T-PLL is highly conserved and characteristic of T-PLL, 3 the target genes of the recurrent secondary aberrations in this disease are largely unknown, except ATM, which is supposed to be the tumor suppressor gene in the commonly deleted region in 11q22B23. 11, 12 In various subtypes of leukemias and lymphomas, array-based transcriptional profiling recently identified characteristic gene expression signatures. [13] [14] [15] Moreover, comparative cytogenetic analyses showed these gene expression profiles to be closely related to the presence of recurrent chromosomal changes. [13] [14] [15] [16] To investigate further the molecular pathogenesis of T-PLL, here we performed gene expression profiling (GEP) on purified CD3 þ cells of five fluorescence in situ hybridization (FISH)-verified inv (14) t(14;14)-positive T-PLL diagnosed according to the World Health Organization (WHO) criteria 17 and eight agematched healthy donors using the Affymetrix U133A microarray platform. To identify candidate genes with potential relevance to the disease process, GEP results were then correlated with genomic aberrations detected by FISH and high-density single nucleotide polymorphism (SNP)-based mapping.
Materials and methods

In silico comparative analysis of chromosomal imbalances in T-PLL
In silico comparative analysis of chromosomal imbalances in 67 cytogenetically characterized T-PLL with unequivocal descrip-tion of a t/inv(14;14)(q11;q32) obtained from the Mitelman Database of Chromosome Aberrations in Cancer (http://cgap. nci.nih.gov/Chromosomes/Mitelman) was performed using the Progenetix software as previously described (www.progenetix. net 18, 19 ).
Patients and sample preparation
The overall experimental strategy pursued in this study is shown in Supplementary Figure 1 . A total of 13 samples were selected for this study, in which the diagnosis of T-PLL was established according to the WHO criteria. 17 Only T-PLLs were included, in which standard chromosome analysis on short-term cultures of the tumor cells using fluorescence R-banding revealed an aberrant karyotype including the typical inv(14)/t (14;14) . Patient characteristics including full karyotypes are given in Supplementary  Table 1 . Fresh material for combined gene expression and genomic profiling was available from five patients with T-PLL (T-PLL1-T-PLL5, Supplementary Table 1) . In seven patients (T-PLL6, T-PLL12) only material for genomic analyses was available. Peripheral blood cells from eight healthy donors served as controls. One T-PLL lacking inv(14)/t(14;14) (patient A, Supplementary Table 1 ) served as an additional (negative) control for comparative analysis of gene expression changes linked to inv(14)/t(14;14) and was also included in the flow cytometric analysis of CD35 expression (see below). All samples were obtained with informed consent from the files of the Department of Hematology, University Hospital Essen, and the Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel. The study was approved by the ethics committee of the faculty of medicine at the University of Duisburg-Essen.
Mononuclear cells were isolated from fresh peripheral blood samples (Lymphoprep, Invitrogen, Karlsruhe, Germany). CD3 þ T cells were enriched employing anti-CD3 magnetic microbeads (MidiMacs, Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in a purity of CD3 þ T cells of 490% by flow cytometry.
GEP and statistical analysis of gene expression data GEP was performed on RNA from 1 to 2 Â 10 8 CD3 þ cells (RNeasy midi kit, Qiagen, Hilden, Germany) using the Affymetrix U133A microarray platform as recently described. 20 Differentially expressed genes (Supplementary Table 2) were identified using non-parametric Mann-Whitney U-test and the significance analysis of microarrays method 21 in a supervised approach as described in the legend of Supplementary Table 2 . The panel of differentially expressed genes was further functionally analyzed for enrichment in the gene ontology (GO) categories 'biological process' and 'molecular function' employing the GO stat tool (Supplementary Table 3) . 22 Furthermore, differentially expressed genes (Supplementary  Table 2 ) were tested for nonrandom distribution to individual chromosome arms employing the hypergeometric distribution method 23 to identify candidate regions for genomic aberrations (Table 1) . With this distribution, the probability of observing at least x probe sets, which represent genes located on one chromosome is given by
where N is the number of probe sets with known chromosomal location (here 19416), n the number of differentially expressed probe sets with known chromosomal location (here 830) and K the number of probe sets, which represent genes located on the respective chromosome. 25 GeneChip analyses. GeneChip analyses were conducted as recently described. 26 Genomic DNA (extracted with QIAamp DNA Blood Midi Kit, Qiagen, Hilden, Germany) was subjected to Affymetrix GeneChip 50K SNP XbaI mapping array analyses following the standard protocol for Affymetrix GeneChip Mapping 100 K arrays (Affymetrix Inc., Santa Clara, CA, USA). Arrays were evaluated using the Affymetrix software tools Table 1 Hypergeometric distribution analysis of T-PLL vs normal donor T-cell distinction genes for enrichment (clustering) on individual chromosome arms (see Materials and methods for statistical details) Immunoblot analysis of ankyrin-1
T-PLL cells, ND PBMNCs and Jurkat cells were homogenized in a hypotonic Tris/HCl buffer. The 1000 g supernatant was centrifuged for 20 min at 100 000 g and the resulting pellets were resuspended. After determination of the protein concentration, an equal amount, representing 25 mg per lane, was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoretically separated proteins were transferred to nitrocellulose membranes and incubated with phosphate-buffered saline (PBS) containing 10% milk powder to block unspecific protein-binding sites. Thereafter, stripes were incubated for 16 h at 41C with an antiserum directed against human ankyrin in appropriate dilution in PBS/10% milk powder as previously described. 27 Washing steps were performed with PBS containing 0.05% Tween-20. The bound immunoglobulins were incubated with horse radish peroxidase (HRP)-labeled antiserum raised against rabbit immunoglobulin G and chemoluminescence was visualized using the enhanced chemiluminescence (ECL) detection system (Amersham Braunschweig, Germany). As a positive control, human erythroid membranes (human ghosts, HGs) were used. 27 
Results
In silico comparative analysis of chromosomal imbalances T-PLL cases Figure 1a shows an in silico comparative analysis 18, 19 of 67 cytogenetically characterized T-PLL cases with unequivocal description of a t/inv(14;14)(q11;q32) obtained from the Mitelman Database of Chromosome Aberrations in Cancer (http:// cgap.nci.nih.gov/Chromosomes/Mitelman). Highly recurrent secondary changes as detected by standard metaphase cytogenetics include overrepresentations of 8q and deletions of 8p, frequently due to formation of an isochromosome iso(8q), as well as losses on chromosome 11 and with lower frequency involving other chromosomal regions like 22q and 6q. Figure 1b shows the profiles of 31 T-PLL cases analyzed by comparative genomic hybridization (CGH), derived from the Progenetix database (www.progenetix.net). In the cases analyzed by CGH (Figure 1b) , additional genomic imbalances such as gains on 6p, 14qter and 22q, and more clearly delimited regional changes like a deletion hot spot in 11q22 Bq23 are apparent.
GEP
The transcriptomes of CD3-purified cells from the peripheral blood of five inv(14)-positive T-PLL cases were compared with those of eight ND-derived immunomagnetically purified peripheral blood T-cell samples using the Affymetrix U133A platform (Supplementary Figure 1) .
Applying the filter and evaluation strategies outlined in Supplementary Figure 1 and in Materials and methods, supervised comparative analysis revealed that a total of 435 probe sets (392 genes) were significantly upregulated and 395 probe sets (342 genes) were significantly downregulated in the T-PLL samples (Supplementary Table 2 ) as compared to the normal controls.
Deregulation of genes directly linked to inv(14)/ t (14;14) . Among the genes significantly upregulated in the T-PLL samples was TCL1A located at the TCL1 locus in 14q32.1. In line with previous reports 8, 9 and despite the FISH-proven presence of inv (14)/t(14;14) in all five T-PLL samples studied, no consistent upregulation of the genes TCL1B, TNG1 or TNG2 at the TCL1 locus was observed ( Figure 2 ). However, in one-fifth of T-PLL samples, TNG1 was found to be unequivocally upregulated, whereas its expression was absent in all of the remaining T-PLL cases and the normal controls ( Figure 2) . Conversely, an inv(14)/t(14;14)-negative T-PLL sample (patient A, see Supplementary Table 1 ) lacked overexpression of TCL1A or any other gene at the TCL1 locus ( Figure 2) . Expression from the TCRAD locus in 14q11 was decreased in all T-PLL samples (Supplementary Table 2 ). Residual expression of TCRA detectable in all five T-PLL most likely originated from the TCRAD locus not involved in the inv(14)/t(14;14). 28, 29 Molecular pathway analysis of GEP data and identification of genes with potential importance for the pathogenesis of T-PLL. To elucidate further the biological processes and molecular pathways deregulated in T-PLL, the panel of differentially expressed genes (Supplementary Table 2 ) was functionally analyzed for enrichment in the GO categories 'biological process' and 'molecular function' employing the GO stat tool. 22 This analysis revealed significant enrichment of genes comprised in the 'cell surface receptorlinked signal transduction', 'defense response' and 'immune response' GO-biological process, and 'receptor activity' and 'transmembrane receptor activity' GO-molecular function categories (Supplementary Table 3 ), respectively. Several of the genes upregulated in T-PLL are involved in regulation of transcription, nucleosome assembly, translation and cell cycle control (for example, Nijmegen breakage syndrome 1 (NBS1), TCF7L, CCNB2, CCNB1, CCNG2, PFAS, PAICS, HIST1H2AE, HIST1H2B, HIST1H4G, ELF4EBP1, ELL3). In contrast, various pro-apoptotic genes like FAS, CASP1, CASP4, CASP8, STK17A and TRAIL were down-modulated (Supplementary  Table 2 ). This expression pattern might provide the leukemic cells with an increased proliferative drive and reduced susceptibility to apoptotic cell death, thus explaining the aggressive clinical behavior of these cells in vivo. Similarly, deregulation of the insulin-like growth factor (IGF) system Figure 1 In silico comparative analysis of chromosomal imbalances in 67 cytogenetically characterized T-PLL cases (a) with unequivocal description of a t/inv(14;14)(q11;q32) obtained from the Mitelman Database of Chromosome Aberrations in Cancer (http://cgap.nci.nih.gov/ Chromosomes/Mitelman). 19 (b) Profiles of 31 T-PLL cases analyzed by comparative genomic hybridization (CGH), derived from the Progenetix database (www.progenetix.net; 18, 19 ). For most of these cases, no information about structural chromosomal abnormalities was available. The output gives a summary of the imbalances determined by conventional cytogenetics (a) or CGH (b) as percentage of cases in the data set, showing the respective change on the corresponding band. A loss of genomic material is indicated by an amplitude to the left and colored in red, a gain of genomic material is marked by an amplitude to the right and green color. As per convention, 3 chromosomal regions that were involved in more than 20% of the cases analyzed were referred to as recurrent.
T-cell prolymphocytic leukemia
J Dürig et al through increased expression of IGFBP5 and IGFBP7 (Supplementary Table 2 ) in T-PLL might promote leukemic cell growth.
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Of note, CR1 encoding complement component (3b/4b) receptor 1 (CD35) was found to be 18.6-fold upregulated in the T-PLL samples (P ¼ 0.017, Supplementary Table 2 ). Although T-cell prolymphocytic leukemia J Dürig et al limited to a subset of 4/7 cases, differential surface expression of the CR1/CD35 protein was confirmed using multiparameter flow cytometry in a series of seven T-PLL samples where viably frozen cells were available for analysis vs 10 normal controls ( Figure 3) . Thus, CD35 could serve as a novel diagnostic marker in at least a subset of T-PLL.
Hypergeometric distribution analysis of GEP data. Testing the 830 probe sets differentially expressed between T-PLL and normal controls (Supplementary Table 2A) for nonrandom distribution to individual chromosomes using the 'hypergeometric distribution method' 23 revealed highly significant enrichment (Pp0.01) of upregulated genes on chromosome arms 6p and 8q and of downregulated genes on 6q, 8p, 10p, 11q and 18p (Table 1) . Thus, at the chromosome-arm-specific-level clustering of deregulated genes is closely correlated with the typical pattern of chromosomal imbalances in T-PLL (Figure 1 ) and suggests 10p and 18p as novel potential targets in the pathogenesis of this T-cell neoplasm. In total, 186 of 830 differentially expressed probe sets (22%) were found to be significantly enriched in chromosomal regions shown to be affected by genomic aberrations secondary to inv(14)/t(14;14). Some of these candidate genes are involved in DNA repair (NBS1, ATM), regulation of apoptosis (CASP1, CASP4) and nucleosome assembly. Histone genes including HIST1H2AE, HIST1H2B, HIST1H4G may play an important functional role in disease progression and thus, could serve as interesting targets for the development of novel therapeutic agents.
Genome mapping using SNP-based arrays and FISH Copy-number changes. To refine chromosomal aberrations associated with clustering of deregulated genes, Affymetrix GeneChip 50K SNP XbaI mapping array analyses were performed in a total of 11 T-PLL with inv(14)(q11q32) or t(14;14)(q11;q32), including those subjected to gene expression analyses, and one T-PLL case without inv(14)/t(14;14) (Supplementary Table 1 ). Recurrent regions of gains in 6p (3/12) and 8q (10/12) and of losses in 6q (5/12), 8p (7/12) and 11q (3/12) were usually large, ranging from 25.8 to 72.3 Mb in size (Table 2 ). In line with the enrichment of downregulated genes, novel regions of recurrent losses were detected in 10p (4/12 cases, minimal deleted region 3.2 Mb) and 18p (10.3 Mb) in 3/12 T-PLL (Tables 2 and 4 ). Three T-PLL cases carried the characteristic iso(8q) and six others a cytogenetically proven der(8p). High-resolution mapping of the breakpoints associated with loss of 8p and gain of 8q revealed scattering of the breakpoints over 7.2 Mb in 8p12-8p11.21 (34.6-41.8 Mb) (Figure 4) , which is in line with previous reports. 31 Similar to chromosome 8, the breakpoints of the recurrent 6qÀ (n ¼ 5) scattered over two chromosomal regions of 27.8 and 37.9 Mb and the breakpoints of the typical dim/enh(22q) (n ¼ 4) over a region of 9 Mb. SNP array data compared favorably to FISH results with respect to copy number in the samples, with 28 of 32 SNP array tests matching FISH copy-number data (Supplementary Table 5 ).
Uniparental disomy. It has recently been shown that allelic loss may be caused by mechanisms other than loss of copy number. 32 Functional allelic loss occurs when one allele is deleted and the remaining dysfunctional allele is duplicated resulting in copy-number neutral loss of heterozygosity (LOH). Uniparental disomy (UPD) can be detected by SNP-mapping array technology and has recently been shown to play an important role in the molecular pathogenesis of various malignancies including acute myeloid leukemia and multiple myeloma. 15, 32, 33 Here, we defined partial UPD (pUPD) as a region spanning at least 50 SNPs with homozygous allele calls T-cell prolymphocytic leukemia J Dürig et al and a Àlog 10 (P-value) for LOH above 15 in the absence of a deletion. 34 Using these criteria, two cases showed an overlapping region of UPD in 3q (Table 3 ). There are eight nonrecurrent regions of pUPD on chromosomes 3 (one region), 6 (four regions), 9, 11 and 13 (one region each). The average size of UPD is 4 Mb. It is interesting to note, that in five instances occurrence of pUPD was associated with a change in copy number on the same chromosome arm (Table 3) .
Integration of SNP-based genomic mapping and GEP of chromosome 8
As described above and in previously published works, 3, 6 alterations of chromosome 8 represent the most common aberration secondary to inv(14)/t(14;14) in T-PLL. Figure 4 gives an integrated overview of SNP chip (N ¼ 11) and GEP (N ¼ 5) results obtained from all of the samples with proven inv(14)/ t(14;14) (Supplementary Table 1 ). In total, 62 of 830 (7.5%) probe sets found to be differentially expressed between T-PLL and ND-derived T-cell samples were located on chromosome 8 (Supplementary Table 2, Table 1 ). Interestingly, consistent with the loss of chromosomal material on 8p we found that the expression of the tumor suppressor gene MTUS1 35 was significantly downregulated as compared to normal controls. Also in accordance with the gain of chromosomal material, 40/ 41 differentially expressed genes located on 8q were found to be upregulated (Table 1) . Potentially important, this set of genes included NBS1 or nibrin, the overexpression of which has T-cell prolymphocytic leukemia J Dürig et al recently been shown to contribute to the oncogenic transformation of head and neck cancer and non-small cell lung cancer cells through the activation of the PI3/Akt pathway. [36] [37] [38] Furthermore, chromosome 8 aberrations were associated with aberrant expression of the erythrocytic structural membrane protein ankyrin-1, which was absent in the eight normal control samples and the T-PLL case lacking iso(8q) (see T-PLL 3 in Figure 4 ). Aberrant expression of ankyrin-1 was confirmed at the protein level using western blot ( Figure 5 ).
Discussion
The advent of high-density SNP array technology allows for the high-resolution analysis of copy-number changes and copynumber neutral allelic loss caused by UPD. Combining SNP array-derived genomic information with data generated by gene expression arrays obtained from the same tumor samples provides a powerful tool for the identification of pathologically relevant genes. 15 Here, we applied this integrated SNP-based mapping and expression array approach to peripheral blood samples from patients with T-PLL defined by WHO diagnostic criteria 17 and the presence of inv(14)/t (14;14) . Because of the rarity of the disease, our study was limited to tumor samples from a cohort of 12 patients (Supplementary Table 1 ). For all of these cases, viably frozen PBMNCs with a tumor cell content of 460% were available for DNA extraction and subsequent SNParray analysis. However, due to technical considerations GEP was performed on fresh immunomagnetically purified tumor samples only and thus restricted to a subset of five tumor samples. Despite the small size of the study cohort, we observed highly significant changes in the gene expression profiles of T-PLL cells as compared to ND-derived T cells, thereby providing a focus for further studies of the molecular pathogenesis of this disease.
The primary oncogenic event in T-PLL appears to be an inversion or translocation of chromosome 14 that juxtapose enhancer elements of the TCRAD locus at 14q11 next to oncogenes located at 14q32, whose expression is then deregulated. 7, 9 Work by Saitou et al. 39 and the Croce and co-workers 40 has identified the presence of four different candidate proto-oncogenes, that is TCL1A, TCL1B, TNG1 and TNG2, located in the breakpoint cluster region at 14q32. The most important of these is the TCL1A gene, which is consistently expressed in T-PLL with inv(14)/t(14;14), but not in normal T cells. Transgenic mouse studies have demonstrated that overexpression of TCL1 induces T-cell malignancies in these animals suggesting that TCL1 plays a causal role in the transformation process. 10 More recently, TCL1 was shown to physically interact with the Akt survival kinase which is then activated and translocated to the nucleus, which may explain at least in part the oncogenic potential of TCL1 at the molecular level. 41 Reassuringly, we found that TCL1A, but not TCL1B and TNG2, was highly expressed in the T-PLL samples, whereas it could not be detected in ND-derived T cells and a T-PLL case lacking inv(14)/t(14;14) (Figure 2 ). These findings support the concept of TCL1A being the primary oncogenic target of inv (14)(q11q32.1) in the T-PLL cases described here. However, it is interesting to note that one out of five T-PLLs but none of the normal controls also overexpressed TNG1 (Figure 2 ). This observation is in accordance with a study by Hallas et al. 40 suggesting that inv(14)/t (14;14) can induce the coordinate overexpression of other genes than TCL1A at 14q32 at least in some cases of T-PLL. 40 In their report, Saitou et al. 39 argued that TNG1 and TNG2 represent different isoforms of the TCL6 gene rather than independent genes. These authors suggest that TCL6 just as TCL1 could serve as a candidate oncogene involved in the malignant transformation of T cells. 39 Besides the primary oncogenic aberration on chromosome 14, T-PLL cells usually harbor a high load of additional chromosomal abnormalities (Figure 1 ). The pattern of secondary Table 3 Regions of pUPD in T-PLL Abbreviations: LOH, loss of heterozygosity; n.c., no change of copy number; pUPD, partial uniparental disomy; SNP, single nucleotide polymorphism. pUPD was defined as a region spanning at least 50 SNPs with homozygous allele calls and a Àlog 10 (P-value) for LOH above 15 in the absence of a deletion. chromosomal changes detected by SNP array in this study (Table 2) tallies well with previously reported data sets. 3, 6 Of note, in addition to the known characteristic chromosomal imbalances shown in Figure 1 , we observed as yet undescribed novel recurrent aberrations affecting 10p and 18p. More importantly, hypergeometric distribution analysis of GEP data revealed that 22% of the probe sets found to be differentially expressed between T-PLL and normal T cells map to chromosomal regions affected by recurrent imbalances occurring secondary to inv(14)/t(14;14) ( Table 1 ). Some of these candidate genes are involved in DNA repair (ATM, DLCRE1C), regulation of apoptosis (CASP1, CASP4) and nucleosome assembly. Several histone genes (Supplementary Table 2 and Table 4) found to be overexpressed due to a gain of chromosomal material on 6p may play an important functional role in disease progression and thus could serve as interesting targets for the development of novel therapeutic agents. The short arm of chromosome 8 is a frequent target of genetic alterations in a wide variety of human cancers 42 including breast cancer 43 and T-PLL. 3, 6 We found that T-PLL cases exhibiting a DNA amplification at 8p11.1 aberrantly express the erythrocytic structural membrane protein ankyrin-1 both at the mRNA and protein level. Ankyrins are a family of proteins that are believed to link the integral membrane proteins to the underlying spectrin-actin cytoskeleton and play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. 27, 44 It is thus tempting to speculate that aberrant expression of this molecule may contribute to the abnormal migratory behavior of T-PLL cells as evidenced by the commonly observed tumor cell infiltration of the skin and peritoneal cavity. 2 Even more strikingly, we observed a highly significant 2.3-fold overexpression of the NBS1/nibrin gene in T-PLL samples with a gain of chromosomal material on 8q as compared to normal controls ( Figure 4 ). Increased NBS1 expression has been observed in non-small cell lung carcinoma, hepatoma, melanoma and esophageal cancer samples. [36] [37] [38] Furthermore, Chen et al. 36 have recently demonstrated that constitutive expression of NBS1 in Rat1a and HeLa cells induces/enhances their transformation through stimulation of phosphatidylinositol (PI)3-kinase activity, leading to increased phosphorylation levels of Akt and its downstream targets such as mammalian target of rapamycin. It is thus tempting to speculate that increased NBS1 expression contributes to TCL1-induced enhanced Akt signaling in T-PLL cells, which has been suggested to be causal for disease progression. 41 Copy-number neutral LOH (UPD) is increasingly recognized as an important genetic mechanism in cancer biology where silencing of tumor suppressor genes may play a role in the transformation process and disease progression. 15, 32 Here, we describe for the first time the occurrence of pUPD in 7 out of 11 T-PLL cases analyzed by SNP-array technology. We found eight non-recurrent regions of pUPD interspersed throughout the genome predominantly affecting chromosome 6 (four regions), and identified two cases showing an overlapping region of pUPD in 3q (Table 3) . Interestingly, in 5 out of 10 instances, pUPD was associated with a copy-number change observed on the same chromosome arm suggesting that the genetic mechanisms underlying these abnormalities may be linked. The detection of UPD in T-PLL raises the possibility of identifying functionally important genes that are downregulated through epigenetic mechanisms or mutations but retain a Table 4 Overview of deregulated genes in the critical regions with their localization and genomic alteration diploid copy number. In this context, a combined SNP array and global GEP approach could provide a useful tool to identify such candidate genes. Unfortunately, in our present study, the small number of cases analyzed by both GEP and SNP array (N ¼ 5) precluded a meaningful analysis of gene expression changes in regions affected by pUPD.
Ankyrin
In conclusion, comparative transcriptional and molecular cytogenetic profiling in T-PLL with inv(14)(q11q32) demonstrates that a substantial number of the deregulated genes map to genomic regions targeted by recurrent chromosomal aberrations suggesting that a gene dosage effect may play a role in the disease process (Table 4 ). The upregulated expression of genes involved in chromatin composition and PI3K/Akt signaling detected in the present study along with ATM defects might point to a pathogenic role of altered DNA repair, nucleosome assembly and cell survival. Finally, we have identified novel regions of recurrent chromosomal imbalances and candidate genes, providing a focus for further studies addressing the molecular pathogenesis and novel treatment strategies in T-PLL.
